Clinical trials: Sexually Transmitted Diseases, Viral
Human Papillomavirus Infections
GARDASIL™ Vaccine Impact in Population Study (V501-033)
This study will assess the impact of GARDASIL™ human papillomavirus (HPV) vaccine in the general female population by utilizing nationwide registry databases in the participating Nordic countries.
- Trial name
- VIP (NCT01077856)
- Volunteers
- 54,516 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
A Study to Demonstrate That Anti-HIV Drug Therapy Can be Stopped Without Causing Viral Resistance, and to Characterize Drug Elimination From the Body
The purpose of this study is to find out if anti-HIV drugs can be stopped without the virus becoming resistant to the drugs. The study will also examine how fast anti-HIV drugs leave the body.
- Trial name
- NCT00029341
- Testing
- Treatment Interruption
- Where
- 7 sites in United States
- Volunteers
- 36 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV, AIDS
Smoking Cessation for People Living With HIV/AIDS
In this proposed study with People Living with HIV/AIDS (PLWHA), we will use a stepped care model called a Sequential Multiple Assignment Randomized Trial (SMART) to examine the efficacy of low- and high-intensity smoking…
- Conditions
- HIV, AIDS, Nicotine Dependence
- Trial name
- NCT01965405
- Testing
- Bupropion, Brief Counseling, High-magnitude prize contingency management
- Where
- United States
- Volunteers
- 165 people
- Sponsor
- Wayne State University
HIV/AIDS
Risk of CV Events With EFV vs. EFV-free Regimens
The purpose of this study is to determine whether there is an increased risk of cardiovascular events (CV) with regimens containing efavirenz (EFV) versus other regimens in patients with HIV.
- Trial name
- NCT02426866
- Testing
- Efavirenz
- Volunteers
- 29,612 people
- Sponsor
- Bristol-Myers Squibb
HIV Infections
Dideoxycytidine ( Ro 24-2027 ). A Treatment Protocol for the Use of Dideoxycytidine ( ddC ) in Patients With AIDS or Advanced ARC Who Cannot Be Maintained on Zidovudine ( AZT ) Therapy.
To provide zalcitabine ( ddC ) for patients with AIDS or Advanced ARC in whom zidovudine ( AZT ) is contraindicated, or who have failed treatment with or are intolerant to AZT and to demonstrate that ddC monotherapy is safe, and…
- Trial name
- NCT00002256
- Testing
- Zalcitabine
- Where
- United States
- Sponsor
- Hoffmann-La Roche
HIV Infections
Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Females
This study will establish the minimum safety, tolerability and acceptability data needed to support the use of cabotegravir long-acting injection (CAB LA) in an adolescent population, potentially transforming the field of HIV…
- Trial name
- NCT04824131
- Testing
- Oral cabotegravir (CAB), CAB LA, Oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)
- Where
- 3 sites in South Africa, Uganda and 1 more
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Spirituality and Will to Live in Patients With HIV/AIDS
This study is assessing the extent of spirituality in patients with HIV/AIDS and will determine the relationship between spirituality, health status, and the will to live.
- Trial name
- NCT00122902
- Where
- United States
- Volunteers
- 350 people
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
Infections, Papillomavirus
Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in HIV Infected Females
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. The current study is designed to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' HPV vaccine…
- Trial name
- NCT00586339
- Testing
- Cervarix
- Where
- South Africa
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV Infection
UNIVERSAL 1: Pharmacokinetic Study of a Novel DTG/FTC/TAF Dose Ratio for Children
This study aims to find out whether treating children living with HIV with three anti-HIV medicines, dolutegravir (DTG), emtricitabine (FTC) and tenofovir alafenamide (TAF), with a novel dose ratio will achieve adequate drug…
- Trial name
- UNIVERSAL1 (NCT05993767)
- Testing
- dolutegravir (DTG)/emtricitabine (FTC)/tenofovir alafenamide (TAF) regimen, Dolutegravir (DTG)/ Emtricitabine (FTC)/tenofovir alafenamide (TAF)
- Where
- 3 sites in Uganda, Zimbabwe
- Volunteers
- 53 people
- Sponsor
- PENTA Foundation
Human Papillomavirus Infections
ICI-VPH: Impact of HPV Immunisation Schedules Against HPV
This randomised clinical trial aims to determine whether an immunization schedule comprising two doses of Gardasil administered six months apart is non-inferior to a schedule comprising three doses administered at 0, 6 and 60…
- Trial name
- ICI-VPH (NCT02009800)
- Testing
- Quadrivalent HPV vaccine
- Where
- 2 sites in Canada
- Volunteers
- 3,364 people, healthy volunteers welcome
- Sponsor
- CHU de Quebec-Universite Laval
HIV Infections, Alcohol Drinking
Boston Alcohol Research Collaboration on HIV/AIDS (ARCH) Cohort: The 4F Study
The purpose of this study is to follow a cohort of HIV-infected adults who have alcohol and/or drug use to: 1) test the associations between alcohol (and illicit drugs and polypharmacy (multiple prescribed medications)) and falls…
- Conditions
- HIV Infections, Alcohol Drinking, Substance-Related Disorders, Bone Diseases
- Trial name
- NCT03414411
- Where
- United States
- Volunteers
- 251 people
- Sponsor
- Boston University
Human Papillomavirus Infection
A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) Vaccine
This Study to Evaluate the Immunogenicity and Safety of Candidate Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli) Administered Intramuscularly in Healthy Female…
- Trial name
- NCT06207175
- Testing
- Nonavalent HPV study vaccine, GARDASIL® 9
- Where
- Indonesia
- Volunteers
- 1,260 people, healthy volunteers welcome
- Sponsor
- Beijing Health Guard Biotechnology, Inc
HIV Infections
Raltegravir Treatment in Patients Failing Highly Active Antiretroviral Therapy (HAART) in Denmark
Raltegravir is the first integrase inhibitor approved for treatment of HIV infected patients harboring multiresistant viruses. The drug has been proved effective in both trials and clinical settings, but the long-term efficacy is…
- Trial name
- NCT01061957
- Where
- Denmark
- Volunteers
- 96 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
HIV Infections
HIV Symptom Management Program for African American Mothers
African American mothers infected with HIV face unique challenges in management of their disease. The goal of this study was to determine the effectiveness of an HIV self-care and symptom management program designed to help…
- Trial name
- NCT00065819
- Testing
- HIV Symptom Education Program
- Where
- United States
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
HIV Infections
A Comparison of Different Community Models of ART Delivery Amongst Stable HIV+ Patients in Two Urban Settings in Zambia
The purpose of this study is to compare the virological and clinical outcomes of patients participating in community models of ART delivery to the standard of care in an urban setting in Zambia.
- Trial name
- NCT03025165
- Testing
- Community Adherence Clubs, Home-Based ART Delivery, Standard of Care
- Where
- Zambia
- Volunteers
- 2,526 people, healthy volunteers welcome
- Sponsor
- HIV Prevention Trials Network
Substance Abuse, Intimate Partner Violence (IPV)
SER Familia: A Family-Based Intervention Addressing Syndemic Conditions Among Latino Families
This study aims to prevent syndemic health conditions by decreasing acculturative stress and promoting resilience via SER Familia (Salud, Estrés y Resilencia en Familias/ Health, Stress, and Resilience in Families), a…
- Conditions
- Substance Abuse, Intimate Partner Violence (IPV), HIV Infections, Depression
- Trial name
- SER Familia (NCT06627764)
- Testing
- SER Familia
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Duke University
Infections, Papillomavirus
Evaluation of Safety of a Vaccine Against Cervical Cancer in Healthy Korean Females
This Post Marketing Surveillance (PMS) will collect safety data on the use of GSK Biologicals' human papillomavirus (HPV) vaccine in the local target population of females as per the regulations of the Korean Food and Drugs…
- Trial name
- NCT01101542
- Testing
- Cervarix., Data collection
- Where
- 2 sites in South Korea
- Volunteers
- 3,091 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cytomegalovirus Retinitis, HIV Infections
An Open-Label Study of the Safety and Efficacy of Cidofovir for the Treatment of Relapsing Cytomegalovirus Retinitis in Patients With AIDS
To evaluate the safety and tolerance of cidofovir (HPMPC) infusions in AIDS patients with relapsing cytomegalovirus (CMV) retinitis. To determine the time to retinitis progression in this patient population.
- Trial name
- NCT00002142
- Testing
- Cidofovir, Probenecid
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Gilead Sciences
Papillomavirus Infections
Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.
The purpose of this study was to evaluate efficacy of 851B gel over a range of concentrations and dosing regimens on high-risk cervical human papillomavirus infection in women.
- Trial name
- NCT00312286
- Testing
- 851B
- Where
- 93 sites in United States, Canada and 1 more
- Volunteers
- 538 people
- Sponsor
- Takeda
Head and Neck Squamous Cell Carcinoma (HNSCC), HPV (Human Papillomavirus)-Associated Carcinoma
A Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects With HPV Positive HNSCC.
BVAC-E6E7 is an immunotherapeutic vaccine designed to treat unresectable recurrent or metastatic head and neck squamous cell carcinoma positive to HPV 16 or 18.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC), HPV (Human Papillomavirus)-Associated Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT06797986
- Testing
- BVAC-E6E7 (low level), BVAC-E6E7 (high level), BVAC-E6E7 (RP2D)
- Where
- 2 sites in South Korea
- Volunteers
- 37 people
- Sponsor
- Cellid Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.